Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis

Roberto Fogari, Pamela Maffioli, Amedeo Mugellini, Annalisa Zoppi, Pierangelo Lazzari, Giuseppe Derosa

Research output: Contribution to journalArticle

Abstract

Objectives: The inhibition of the renin-angiotensin system and of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase could improve hepatic steatosis. The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis. Methods: Patients were treated with losartan, 100 mg/day, or amlodipine, 10 mg/day, for 6 months; subsequently simvastatin, 20 mg/day was added to both treatments for a further 6 months. The patients performed an ultrasound examination [steatosis degree, subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) diameter], an euglycemic hyperinsulinemic clamp [glucose infusion rate (GIR)], and a blood sample (fasting plasma glucose, fasting plasma insulin, triglycerides, and inflammatory parameters) at baseline, and after 6 and 12 months, respectively. Results: Both losartan and amlodipine induced a significant and similar systolic blood pressure/diastolic blood pressure reduction (P

Original languageEnglish
Pages (from-to)164-171
Number of pages8
JournalEuropean Journal of Gastroenterology and Hepatology
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 2012

Keywords

  • amlodipine
  • hypertension
  • insulin sensitivity
  • losartan
  • steatosis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis'. Together they form a unique fingerprint.

  • Cite this